107 related articles for article (PubMed ID: 30178381)
21. Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells.
Karpova D; Ritchey JK; Holt MS; Abou-Ezzi G; Monlish D; Batoon L; Millard S; Spohn G; Wiercinska E; Chendamarai E; Yang W; Christ S; Gehrs L; Schuettpelz LG; Dembowsky K; Pettit AR; Rettig MP; Bonig H; DiPersio JF
Blood; 2017 May; 129(21):2939-2949. PubMed ID: 28400375
[TBL] [Abstract][Full Text] [Related]
22. Functional potentials of human hematopoietic progenitor cells are maintained by mesenchymal stromal cells and not impaired by plerixafor.
Ludwig A; Saffrich R; Eckstein V; Bruckner T; Wagner W; Ho AD; Wuchter P
Cytotherapy; 2014 Jan; 16(1):111-21. PubMed ID: 24119647
[TBL] [Abstract][Full Text] [Related]
23. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
24. Evidence for the involvement of sphingosine-1-phosphate in the homing and engraftment of hematopoietic stem cells to bone marrow.
Adamiak M; Borkowska S; Wysoczynski M; Suszynska M; Kucia M; Rokosh G; Abdel-Latif A; Ratajczak J; Ratajczak MZ
Oncotarget; 2015 Aug; 6(22):18819-28. PubMed ID: 26299919
[TBL] [Abstract][Full Text] [Related]
25. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis.
Theiss HD; Vallaster M; Rischpler C; Krieg L; Zaruba MM; Brunner S; Vanchev Y; Fischer R; Gröbner M; Huber B; Wollenweber T; Assmann G; Mueller-Hoecker J; Hacker M; Franz WM
Stem Cell Res; 2011 Nov; 7(3):244-55. PubMed ID: 21752744
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy-induced niche perturbs hematopoietic reconstitution in B-cell acute lymphoblastic leukemia.
Tang C; Li MH; Chen YL; Sun HY; Liu SL; Zheng WW; Zhang MY; Li H; Fu W; Zhang WJ; Liang AB; Tang ZH; Hong DL; Zhou BS; Duan CW
J Exp Clin Cancer Res; 2018 Aug; 37(1):204. PubMed ID: 30157922
[TBL] [Abstract][Full Text] [Related]
27. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
28. Alteration of rat bone marrow megakaryocytes following administration of cytosine arabinoside, daunomycin and hydroxyurea.
Jerushalmy Z; Payta M; Pinkhas J; De Vries A
Haemostasis; 1977; 6(2):110-7. PubMed ID: 863292
[TBL] [Abstract][Full Text] [Related]
29. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation.
Abraham M; Beider K; Wald H; Weiss ID; Zipori D; Galun E; Nagler A; Eizenberg O; Peled A
Leukemia; 2009 Aug; 23(8):1378-88. PubMed ID: 19322207
[TBL] [Abstract][Full Text] [Related]
30. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.
Tavor S; Eisenbach M; Jacob-Hirsch J; Golan T; Petit I; Benzion K; Kay S; Baron S; Amariglio N; Deutsch V; Naparstek E; Rechavi G
Leukemia; 2008 Dec; 22(12):2151-5158. PubMed ID: 18769446
[TBL] [Abstract][Full Text] [Related]
31. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart.
Huber BC; Brunner S; Segeth A; Nathan P; Fischer R; Zaruba MM; Vallaster M; Theiss HD; David R; Gerbitz A; Franz WM
Cardiovasc Res; 2011 Jun; 90(3):529-37. PubMed ID: 21245057
[TBL] [Abstract][Full Text] [Related]
32. Plerixafor, a CXCR4 antagonist, mitigates skin radiation-induced injury in mice.
Kim JH; Kolozsvary A; Jenrow KA; Brown SL
Radiat Res; 2012 Sep; 178(3):202-6. PubMed ID: 22799631
[TBL] [Abstract][Full Text] [Related]
33. A critical role of Src family kinase in SDF-1/CXCR4-mediated bone-marrow progenitor cell recruitment to the ischemic heart.
Cheng M; Huang K; Zhou J; Yan D; Tang YL; Zhao TC; Miller RJ; Kishore R; Losordo DW; Qin G
J Mol Cell Cardiol; 2015 Apr; 81():49-53. PubMed ID: 25655934
[TBL] [Abstract][Full Text] [Related]
34. Plerixafor induces the rapid and transient release of stromal cell-derived factor-1 alpha from human mesenchymal stromal cells and influences the migration behavior of human hematopoietic progenitor cells.
Wuchter P; Leinweber C; Saffrich R; Hanke M; Eckstein V; Ho AD; Grunze M; Rosenhahn A
Cell Tissue Res; 2014 Feb; 355(2):315-26. PubMed ID: 24337688
[TBL] [Abstract][Full Text] [Related]
35. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
[TBL] [Abstract][Full Text] [Related]
36. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
37. Leukemia Stem Cells Microenvironment.
Tabe Y; Konopleva M
Adv Exp Med Biol; 2017; 1041():19-32. PubMed ID: 29204827
[TBL] [Abstract][Full Text] [Related]
38. Normal and leukemic stem cell niches: insights and therapeutic opportunities.
Schepers K; Campbell TB; Passegué E
Cell Stem Cell; 2015 Mar; 16(3):254-67. PubMed ID: 25748932
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.
Kawaguchi A; Orba Y; Kimura T; Iha H; Ogata M; Tsuji T; Ainai A; Sata T; Okamoto T; Hall WW; Sawa H; Hasegawa H
Blood; 2009 Oct; 114(14):2961-8. PubMed ID: 19657116
[TBL] [Abstract][Full Text] [Related]
40. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis.
Avecilla ST; Hattori K; Heissig B; Tejada R; Liao F; Shido K; Jin DK; Dias S; Zhang F; Hartman TE; Hackett NR; Crystal RG; Witte L; Hicklin DJ; Bohlen P; Eaton D; Lyden D; de Sauvage F; Rafii S
Nat Med; 2004 Jan; 10(1):64-71. PubMed ID: 14702636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
